Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
(1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/1/72 |
| _version_ | 1797443987420741632 |
|---|---|
| author | Qiao Yu Zhigui Li Yuqing Liu Yichen Luo Jingya Fan Peijun Xie Xiaoman Cao Xingyu Chen Xiaodong Wang |
| author_facet | Qiao Yu Zhigui Li Yuqing Liu Yichen Luo Jingya Fan Peijun Xie Xiaoman Cao Xingyu Chen Xiaodong Wang |
| author_sort | Qiao Yu |
| collection | DOAJ |
| description | (1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases. |
| first_indexed | 2024-03-09T13:05:05Z |
| format | Article |
| id | doaj.art-bcc06e2be37245619aee58d4b4e4cfdc |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T13:05:05Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-bcc06e2be37245619aee58d4b4e4cfdc2023-11-30T21:49:52ZengMDPI AGCurrent Oncology1198-00521718-77292023-01-0130194995810.3390/curroncol30010072Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC DatabaseQiao Yu0Zhigui Li1Yuqing Liu2Yichen Luo3Jingya Fan4Peijun Xie5Xiaoman Cao6Xingyu Chen7Xiaodong Wang8Department of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, ChinaDepartment of Gastrointestinal Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610041, China(1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases.https://www.mdpi.com/1718-7729/30/1/72capecitabinemonotherapycolorectal canceradjuvant chemotherapy |
| spellingShingle | Qiao Yu Zhigui Li Yuqing Liu Yichen Luo Jingya Fan Peijun Xie Xiaoman Cao Xingyu Chen Xiaodong Wang Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database Current Oncology capecitabine monotherapy colorectal cancer adjuvant chemotherapy |
| title | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
| title_full | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
| title_fullStr | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
| title_full_unstemmed | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
| title_short | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
| title_sort | effect of different durations of adjuvant capecitabine monotherapy on the outcome of high risk stage ii and stage iii colorectal cancer a retrospective study based on a crc database |
| topic | capecitabine monotherapy colorectal cancer adjuvant chemotherapy |
| url | https://www.mdpi.com/1718-7729/30/1/72 |
| work_keys_str_mv | AT qiaoyu effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT zhiguili effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT yuqingliu effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT yichenluo effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT jingyafan effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT peijunxie effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT xiaomancao effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT xingyuchen effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT xiaodongwang effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase |